Contraline secures $92.5m to push male contraceptive into late-stage trials - Pharmaceutical Technology

Contraline could become the first to commercialise a reversible male contraceptive drug, provided the treatment is successful in Phase III. The Google Ventures-backed company could become the first to commercialise a reversible male contraceptive drug, provided the gel is successful in Phase III. Contraline will use the money to take its topical, reversible male contraceptive to late-stage trials. Credit: NMK-Studio / Shutterstock.com. Contraline has closed a $92.5m Series B financing round to take its topical male contraceptive to late-stage trials – potentially positioning the company with a first-to-market advantage in the male contraceptive market. The funding, which was co-led by…

Source: Pharmaceutical Technology